Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Equity Bottom-Up

<ul><li>TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®).</li><li>It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets.</li><li>Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated seven consecutive reporting periods of strong growth, with TRX becoming profitable in 1H’24.</li></ul>

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®).It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets.Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated seven consecutive reporting periods of strong growth, with TRX becoming profitable in 1H’24.

Tissue Regenix (TRX): Maiden pre-tax profit

<ul><li>For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices.</li><li>This is quite unusual for healthcare stocks.</li><li>Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises.</li></ul>

For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices.This is quite unusual for healthcare stocks.Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises.

Tissue Regenix Group PLC - Hardman & Co Insight: Survival of the UK life sciences sector

<ul><li>TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®).</li><li>It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets.</li><li>Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023.</li></ul>

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®).It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets.Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023.

Hardman & Co Research: Tissue Regenix (TRX) - Six consecutive periods of >20% growth

United Kingdom

Tissue Regenix Group is an international medical technology company specializing in regenerative products using its dCELL® and BioRinse™ platform technologies. These technologies address soft tissue and bone allograft needs through products like DermaPure® for soft tissue repair and ConCelltrate® for bone regeneration, primarily serving the BioSurgery, Orthopaedics, and Dental markets. The company was founded in 2006 in Leeds, UK, and has operations in the UK and US.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tissue Regenix (LSW GR)

Tissue Regenix (TRX): Maiden pre-tax profit

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone...

Hardman & Co

Tissue Regenix Group PLC - Hardman & Co Insight: Survival of the UK life sciences sector

For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This...

Hardman & Co

Hardman & Co Research: Tissue Regenix (TRX) - Six consecutive periods of >20% growth

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone...

Hardman & Co

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)